NewBridge/Verinata enter commercialisation agreement for verifi
NewBridge Pharmaceuticals has established an exclusive agreement with Verinata Health to expand access to Verinata's verifi test, a comprehensive non-invasive prenatal test currently available for high-risk pregnancies. Under the terms of the collaboration agreement, NewBridge will serve as the exclusive Verinata Health commercial partner for the sales and marketing of the verifi test in the countries of the Middle East, Turkey, Africa and Caspian regions. Financial terms of the agreement were not disclosed.
The verifi prenatal test is performed in Verinata's CLIA-certified, California laboratory using a single maternal blood draw as early as ten weeks of pregnancy to detect multiple foetal chromosomal aneuploidies. Using a blood sample from the mother, the verifi test detects Down's syndrome (trisomy 21 or T21), Edwards syndrome (trisomy 18 or T18) and Patau syndrome (trisomy 13 or T13), as well as the most common foetal sex chromosome aneuploidies, including Turner syndrome (Monosomy X), Triple X (XXX), Klinefelter syndrome (XXY) and Jacobs syndrome (XYY).